Sunobinop

Sunobinop
Clinical data
Other namesIMB-115
Drug classNociceptin receptor agonist
Identifiers
IUPAC name
  • 4-[(1R,5S)-9-[(1S,5S)-3-bicyclo[3.3.1]nonanyl]-9-azabicyclo[3.3.1]nonan-3-yl]-3-oxoquinoxaline-2-carboxylic acid
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC26H33N3O3
Molar mass435.568 g·mol−1
3D model (JSmol)
SMILES
  • O=C(O)C1=NC=2C=CC=CC2N(C1=O)C3CC4N(C(CCC4)C3)C5CC6CCCC(C5)C6
InChI
  • InChI=1S/C26H33N3O3/c30-25-24(26(31)32)27-22-9-1-2-10-23(22)29(25)21-14-18-7-4-8-19(15-21)28(18)20-12-16-5-3-6-17(11-16)13-20/h1-2,9-10,16-21H,3-8,11-15H2,(H,31,32)/t16-,17-,18-,19+,21?/m0/s1
  • Key:COTYYZPYDJKKIS-MCXOOUIESA-N

Sunobinop (developmental code name IMB-115) is a nociceptin receptor partial agonist and opioid receptor pan-antagonist.[1] As of March 2022, it is under investigation for the treatment of insomnia, fibromyalgia, and overactive bladder.[1][2]

See also

References

  1. 1 2 "Sunobinop - Shionogi/Imbrium Therapeutics". AdisInsight. Springer Nature Switzerland AG.
  2. ↑ WO application 2018020418, Harris SC, Kapil RP, Kyle DJ, Whiteside G, "Treatment and prevention of sleep disorders", published 2018-02-01, assigned to Purdue Pharma L.P.



This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.